41. Impellizeri J., Aurisicchio L., Forde P., Soden D.M. Electroporation in veterinary oncology. Veterinary Journal. 2016. Vol. 217. P. 18–25. Doi: 10.1016/j.tvjl. 2016.05.015

42. Single exponential decay waveform; a synergistic combination of electroporation and electrolysis (E2) for tissue ablation/ N. Klein et al. Peer J. 2017. Vol. 5: e3190. Doi: 10.7717/peerj.3190

43. Spugnini E.P., Fanciulli M., Citro G., Baldi A. Preclinical models in electrochemotherapy: the role of veterinary patients. Future Oncology. 2012. Vol. 8 (7). P. 829–837. Doi: 10.2217/fon.12.64

44. Irreversible electroporation (NanoKnife) in cancer treatment/ N. Jourabchi et al. Gastrointestinal Intervention. 2014. Vol. 3. P. 8–18. Doi: 10.1016/j.gii.2014.02.002

45. Jarm T., Cemazar M., Miklavcic D., Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert review of anticancer therapy. 2010. Vol. 10 (5). P. 729–746. Doi: 10.1586/era.10.43

46. Thomson K.R., Kavnoudias H., Neal R.E. Introduction to Irreversible Electroporation–Principles and Techniques. Techniques in Vascular and Interventional Radiology. 2015. Vol. 18 (3). P. 128–134. Doi: 10.1053/j. tvir.2015.06.002

47. Beitel-White N., Aycock K.N., Castellví Q., Davalos R.V. Dynamics of cell death after conventional IRE and H-FIRE treatments/ B. Mercadal et al. Annals of Biomedical Engineering. 2020. Vol. 48 (5). P. 1451–1462. Doi: 10.1007/s10439-020-02462-8

48. Sano M.B., Fesmire C.C., DeWitt M.R., Xing L. Burst and continuous high frequency irreversible electroporation protocols evaluated in a 3D tumor model. Physics in Medicine and Biology. 2018. Vol. 63 (13):135022. Doi: 10.1088/1361-6560/aacb62

49. High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity / V.M. Ringel-Scaia et al. EBioMedicine. 2019. Vol. 44. P. 112–125. Doi: 10.1016/j.ebiom.2019.05.036

50. Neal R.E., Garcia P.A., Rossmeisl J.H., Davalos R.V. A study using irreversible electroporation to treat large, irregular tumors in a canine patient. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. Piscataway. 2010. P. 2747–2750. (United States). Doi: 10.1109/IEMBS.2010.5626372

51. Electrolytic ablation enables cancer cell targeting through pH modulation/ N.R. Perkons et al. Communications Biology. 2018. Vol. 1. 48 p. Doi: 10.1038/s42003-018-0047-1

52. Phillips M., Krishnan H., Raju N., Rubinsky B. Tissue ablation by a synergistic combination of electroporation and electrolysis delivered by a single pulse. Annals of Biomedical Engineering. 2016. Vol. 44 (10). P. 3144–3154. Doi: 10.1007/ s10439-016-1624-4

53. Toward a clinical real time tissue ablation technology: combining electroporation and electrolysis (E2) / E. Guenther et al. Peer J. 2020. Vol. 8:e7985. Doi: 10.7717/ peerj.7985 54. Patterns of tumor response in canine and feline cancer patients treated with electrochemotherapy: preclinical data for the standardization of this treatment in pets and humans / E.P. Spugnini et al. Journal of Translational Medicine. 2007. Vol. 5: 48. Doi: 10.1186/1479-5876-5-48

55. Calvet C.Y., Mir L.M. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Reviews. 2016. Vol. 35 (2). P. 165–177. Doi: 10.1007/s10555-016-9615-3

56. Spugnini E.P., Baldi A. Electrochemotherapy in veterinary oncology: state-of-the-art and perspectives. The Veterinary Clinics of North America. Small Animal Practice. 2019. Vol. 49 (5). P. 967–979. Doi: 10.1016/j. cvsm.2019.04.006

57. Fini M., Bonazzi V., Cadossi R., Nicolini A., Carpi A. Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues/ R. Giardino et al. Biomedicine & Pharmacotherapy. 2006. Vol. 60 (8). P. 458–462. Doi: 10.1016/j.biopha.2006.07.016

58. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours / V. Kodre et al. In Vivo. 2009. Vol. 23 (1). P. 55–62. PMID: 19368125

59. Heller L.C., Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Current Gene Therapy. 2010. Vol. 10 (4). P. 312–317. Doi: 10.2174/ 156652310791823489

60. Pavlin D., Cemazar M., Sersa G., Tozon N. IL-12 based gene therapy in veterinary medicine. Journal of Translational Medicine. 2012. Vol. 10: 234. Doi: 10.1186/1479-5876-10-234

61. Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions / J. Cutrera et al. Current Gene Therapy. 2015. Vol. 15 (1). P. 44–54. Doi: 10.2174/1566523214666141127093654

62. Cemazar M., Jarm T., Sersa G. Cancer electrogene therapy with interleukin-12. Current Gene Therapy. 2010. Vol. 10 (4). P. 300–311. Doi: 10.2174/156652310791823425

63. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy / J. Cutrera et al. Journal of Cellular and Molecular Medicine. 2015. Vol. 19 (3). P. 664–675. Doi: 10.1111/jcmm.12382

64. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis/ B. Mali et al. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2013. Vol. 39 (1). P. 4–16. Doi: 10.1016/ j.ejso.2012.08.016

65. Tozon N., Sersa G., Cemazar M. Electrochemotherapy: potentiation of local antitumour effectiveness of cisplatin in dogs and cats. Anticancer Research. 2001. Vol. 21 (4A). P. 2483–2488. PMID: 11724311 66. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity / A. Sedlar et al. Radiology and Oncology. 2012. Vol. 46 (4). P. 302–311. Doi: 10.2478/ v10019-012-0044-9

67. Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer / N. Milevoj et al. Veterinary Medicine and Science. 2020. Vol. 6 (3). P. 290–298. Doi: 10.1002/vms3.232

68. Operating procedures of the electrochemotherapy for treatment of tumor in dogs and cats / N. Tozon et al. Journal of Visualized Experiments. 2016. Vol. 116: 54760. Doi: 10.3791/54760

69. Escoffre J.M., Rols M.P. Electrochemotherapy: progress and prospects. Current Pharmaceutical Design. 2012. Vol. 18 (23). P. 3406–3415. PMID: 22663554.

70. Breast tumour size as a predictor of hemostatic system status and endothelial function in dog/ D.D. Bely et al. Regulatory Mechanisms in Biosystems. 2019. Vol. 10 (3). P. 300–305. Doi: 10.15421/021946

71. Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?/ M.Z. Wojtukiewicz et al. Cancer Metastasis Reviews. 2017. Vol. 36 (2). P. 305–329. Doi: 10.1007/s10555-017-9683-z

72. Placencio V.R., DeClerck Y.A. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Research. 2015. Vol. 75 (15). P. 2969–2974. Doi: 10.1158/0008-5472.CAN-15-0876

73. Tieken C., Versteeg H.H. Anticoagulants versus cancer. Thrombosis research. 2016. Vol. 140 (1). P. 148–153. Doi: 10.1016/S0049-3848(16)30114-1

74. Lanzi C., Cassinelli G. Heparan sulfate mimetics in cancer therapy: the challenge to define structural determinants and the relevance of targets for optimal activity. Molecules. 2018. Vol. 23 (11): 2915. Doi: 10.3390/molecules23112915

75. Franchini M., Mannucci P.M. Direct oral anticoagulants and venous thromboembolism. European respiratory review: an official journal of the European Respiratory Society. 2016. Vol. 25 (141). P. 295–302. Doi: 10.1183/16000617.0025-2016

76. Canine mammary anaplastic carcinoma with concurrent aorto-iliac thrombosis in a dog: a case report/ J. Kim et al. Veterinarni Medicina. 2016. Vol. 60. P. 391–398. Doi: 10.17221/8388-VETMED

77. Losonczy H., Nagy Á., Tar A. A kórházi és az ambuláns kemoterápiában részesülő onkológiai betegek vénásthromboembolia-profilaxisának aktuális kérdései. Actual questions about the prevention of venous thromboembolism in cancer patients receiving chemotherapy. Orvosi hetilap. 2016. Vol. 157 (6). P. 203–211. Doi: 10.1556/650.2016.30357

78. Fletcher D.J., Blackstock K.J., Epstein K., Brainard B.M. Evaluation of tranexamic acid and ϵ-aminocaproic acid concentrations required to inhibit fibrinolysis in plasma of dogs and humans. American Journal of Veterinary Research. 2014. Vol. 75. P. 731–738. Doi: 10.2460/ ajvr.75.8.731

79. Königsbrügge O., Zielinski C., Pabinger I., Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants/ F. Posch et al. Thrombosis Research. 2015. Vol. 136 (3). P. 582–589. Doi: 10.1016/j. thromres.2015.07.011

80. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism / T. van der Hulle et al. Journal of Thrombosis and Haemostasis. 2014. Vol. 12 (7). P. 1116– 1120. Doi: 10.1111/jth.12605

81. Kirkilesis G.I., Kakkos S.K., Tsolakis I.A. Editor's choice - a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. European Journal of Vascular and Endovascular Surgery. 2019. Vol. 57 (5). P. 685–701. Doi: 10.1016/j.ejvs.2018.11.004

82. Pharmacokinetics of tranexamic acid in healthy dogs and assessment of its antifibrinolytic properties in canine blood / K.E. Osekavage et al. American Journal of Veterinary Research. 2018. Vol. 79 (10). P. 1057–1063. Doi: 10.2460/ ajvr.79.10.1057

83. Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice / J. Garona et al. Anticancer Research. 2014. Vol. 34 (9). P. 4761–4765. PMID: 25202055.

84. Canine mammary anaplastic carcinoma with concurrent aorto-iliac thrombosis in a dog: a case report/ J.H. Kim et al. Veterinarni Medicina. 2015. Vol. 60. P. 391–398. Doi: 10.17221/8388-VETMED

85. Kim J.H., Park H.M. Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase. Journal of Veterinary Medical Science. 2012. Vol. 74 (5). P. 657–661. Doi: 10.1292/jvms.11-0432

86. Yin W., Zhang J.G., Jiang Y., Juan S.A. Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice. Experimental and Therapeutic Medicine. 2014. Vol. 8. P. 1213–1218. Doi: 10.3892/etm.2014.1911

87. Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade / Hermo G.A. et al. Journal of the American Animal Hospital Association. 2011. Vol. 47 (1). P. 21–27. Doi: 10.5326/JAAHA-MS-5509

88. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin/ D.F. Alonso et al. Current Рharmaceutical Biotechnology. 2011. Vol. 12 (11). P. 1974–1980. Doi: 10.2174/ 138920111798377076

89. Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies/ C. Frere et al. Cancers. 2019. Vol. 11 (11): 1639. Doi: 10.3390/ cancers11111639

90. Low molecular weight heparins for current and future uses: approaches for micro- and nano-particulate delivery/ S.S. Ibrahim et al. Drug Delivery. 2016. Vol. 23 (8). P. 2661– 2667. Doi: 10.3109/10717544.2015.1046570

91. Development of low molecular weight heparin based nanoparticles for metastatic breast cancer therapy / H. Sun et al. International Journal of Biological Macromolecules. 2018. Vol. 112. P. 343–355. Doi: 10.1016/j.ijbiomac.2018.01.195

92. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties / S.M. Bae et al. Biomaterials. 2013. Vol. 34 (8). P. 2077–2086. Doi: 10.1016/j.biomaterials.2012.11.020

93. Tang B., Qian Y., Fang G. Development of lipidpolymer hybrid nanoparticles for improving oral absorption of enoxaparin. Pharmaceutics. 2020. Vol. 12 (7): 607. Doi: 10.3390/pharmaceutics12070607

94. Elaskalani O., Berndt M.C., Falasca M., Metharom P. Targeting platelets for the treatment of cancer. Cancers. 2017. Vol. 9 (7). Р. 94. Doi: 10.3390/cancers9070094

95. The antitumor effect of heparin is not mediated by direct NK cell activation / G.R. Rossi et al. Journal of Clinical Medicine. 2020. Vol. 9 (8): E2666. Doi: 10.3390/jcm9082666

96. Pharmacological correction of the hemostasis system for the surgical treatment of females tumors of the mammary gland / D.D. Bely et al. Regulatory Mechanisms in Biosystems. 2018. Vol. 9 (3). P. 353–362. Doi: 10.15421/021852

97. Serebruany V.L., Cherepanov V., Cabrera-Fuentes H.A., Kim M.H. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and Haemostasis. 2015. Vol. 114 (6). P. 1104–1112. Doi: 10.1160/TH15-01-0077

98. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients / A. Gómez-Outes et al. Vascular Health and Risk Management. 2013. Vol. 9. P. 207–228. Doi: 10.2147/ VHRM.S35843

99. Lunsford K., Mackin A. Thromboembolic therapies in dogs and cats: an evidence-based approach. The Veterinary Clinics of North America. Small Animal Practice. 2007. Vol. 37 (3). P. 579–609. Doi: 10.1016/j.cvsm.2007.01.010